These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 32127496)

  • 1. Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
    Kharbanda A; Walter DM; Gudiel AA; Schek N; Feldser DM; Witze ES
    Sci Signal; 2020 Mar; 13(621):. PubMed ID: 32127496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of EGFR signalling by palmitoylation and its role in tumorigenesis.
    Kadry YA; Lee JY; Witze ES
    Open Biol; 2021 Oct; 11(10):210033. PubMed ID: 34610265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Combined Use of Everolimus and Second-Generation Pan-EGRF Inhibitors in
    da Silva-Oliveira RJ; Gomes INF; da Silva LS; Lengert AVH; Laus AC; Melendez ME; Munari CC; Cury FP; Longato GB; Reis RM
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual-targeting of EGFR and Neuropilin-1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant non-small cell lung cancer.
    Kim YJ; Baek DS; Lee S; Park D; Kang HN; Cho BC; Kim YS
    Cancer Lett; 2019 Dec; 466():23-34. PubMed ID: 31521695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induced sensitivity to EGFR inhibitors is mediated by palmitoylated cysteine 1025 of EGFR and requires oncogenic Kras.
    Kharbanda A; Runkle K; Wang W; Witze ES
    Biochem Biophys Res Commun; 2017 Nov; 493(1):213-219. PubMed ID: 28899783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IRS4 promotes the progression of non-small cell lung cancer and confers resistance to EGFR-TKI through the activation of PI3K/Akt and Ras-MAPK pathways.
    Hao P; Huang Y; Peng J; Yu J; Guo X; Bao F; Dian Z; An S; Xu TR
    Exp Cell Res; 2021 Jun; 403(2):112615. PubMed ID: 33894221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
    Ito M; Codony-Servat C; Codony-Servat J; Lligé D; Chaib I; Sun X; Miao J; Sun R; Cai X; Verlicchi A; Okada M; Molina-Vila MA; Karachaliou N; Cao P; Rosell R
    Cell Commun Signal; 2019 Oct; 17(1):137. PubMed ID: 31660987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
    Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway.
    Hou X; Zhou C; Liang Z; Qiu H; Zhou Z; Zheng H; Li Z; Wang Y; Qi X; Lu L; Cao Y; Zheng J
    Phytomedicine; 2023 Dec; 121():155093. PubMed ID: 37783131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
    Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
    Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
    J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-19b enhances proliferation and apoptosis resistance via the EGFR signaling pathway by targeting PP2A and BIM in non-small cell lung cancer.
    Baumgartner U; Berger F; Hashemi Gheinani A; Burgener SS; Monastyrskaya K; Vassella E
    Mol Cancer; 2018 Feb; 17(1):44. PubMed ID: 29455644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
    Wu CY; Carpenter ES; Takeuchi KK; Halbrook CJ; Peverley LV; Bien H; Hall JC; DelGiorno KE; Pal D; Song Y; Shi C; Lin RZ; Crawford HC
    Gastroenterology; 2014 Dec; 147(6):1405-16.e7. PubMed ID: 25311989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.
    Green S; Trejo CL; McMahon M
    Cancer Res; 2015 Dec; 75(24):5378-91. PubMed ID: 26567140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.
    Molina-Arcas M; Hancock DC; Sheridan C; Kumar MS; Downward J
    Cancer Discov; 2013 May; 3(5):548-63. PubMed ID: 23454899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.
    Wang L; Hu H; Pan Y; Wang R; Li Y; Shen L; Yu Y; Li H; Cai D; Sun Y; Chen H
    PLoS One; 2014; 9(2):e88291. PubMed ID: 24533074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis.
    Mortazavi F; Lu J; Phan R; Lewis M; Trinidad K; Aljilani A; Pezeshkpour G; Tamanoi F
    BMC Cancer; 2015 May; 15():381. PubMed ID: 25956913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.
    Zhang J; Park D; Shin DM; Deng X
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):11-6. PubMed ID: 26578706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.
    Gasparini P; Cascione L; Landi L; Carasi S; Lovat F; Tibaldi C; Alì G; D'Incecco A; Minuti G; Chella A; Fontanini G; Fassan M; Cappuzzo F; Croce CM
    Proc Natl Acad Sci U S A; 2015 Dec; 112(48):14924-9. PubMed ID: 26627242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.